Clinical Significance of Detecting CyclinD1 and BCL-2 in Patients with B-Cell Lymphoma by Using Flow Cytometry.

Yan-xiang Cui; Xin-hua Wang; Xun Chen

Return

Clinical Significance of Detecting CyclinD1 and BCL-2 in Patients with B-Cell Lymphoma by Using Flow Cytometry.

Author: Yan-Xiang CUI ¹ ; Xin-Hua WANG ² ; Xun CHEN ³
Author Information

1. Department of Clinical Laboratorial Examination, Huangdao Traditional Chinese Medicine Hospital, Qingdao 266500, Shandong Province, China. E-mail: 4799414014@qq.com.
2. Department of Clinical Laboratory Examination, Yishui Center Hospital, Linyi 276400, Shandong Province, China.
3. Department of Clinical Laboratorial Examination, Huangdao Traditional Chinese Medicine Hospital, Qingdao 266500, Shandong Province, China.
Publication Type:Journal Article
MeSH: Case-Control Studies; Cyclin D1; metabolism; Flow Cytometry; Humans; Lymphoma, B-Cell; diagnosis; metabolism; Proto-Oncogene Proteins c-bcl-2; metabolism
From: Journal of Experimental Hematology 2016;24(1):98-101
CountryChina
Language:Chinese
Abstract:
OBJECTIVETo explore the feasibility and value of detecting CyclinD1 and BCL-2 in patients with B-cell lymphoma by using flow cytometry.
METHODSFifty-three patients with lymphoma were selected, and 50 healthy persons in the same period were selected as control. The expression levels of CyclinD1 and BCL-2 in patients with various subtypes of lymphoma were detected by using flow cytometry (FCM).
RESULTSWhen the dilution time was 1 min and the dilution proportion was 1:20, the cell morphology was the best complete, at the 4 min the cell morphology was best status. The mean fluorescence intensity of CyclinD1 and BCL-2 between persons of control group and patients with B-cell lymphoma showed significant difference, the CyclinD1 level (1.824 ± 0.315) and BCL-2 levels (4.257 ± 0.528) of patients with B-cell lymphoma were obviously higher than the CyclinD1 level (0.634 ± 0.153) and BCL-2 level (1.926 ± 0.328) of persons in control group, the CyclinD1 and BCL-2 expression levels of patients with HL were significantly lower than CyclinD1 and BCL-2 levels of patients with NHL (P < 0.01). After treatment, the expression levels of CyclinD1 and BCL-2 in patients with B lymphoma were significantly lower than these befor treatment.
CONCLUSIONUsing the method of flow cytometry for detecting CyclinD1 and BCL-2 expression levels in lymphoma cells of patients is feasible, and it can be applied clinically to evaluate the treatment efficacy.